Corporate Information

(As of April 1, 2023)

Corporate Profile

| Company Name | OAT Agrio Co., Ltd. |
|--|---|
| Head Office | 8th Floor, NBF Ogawa-machi Bldg. 1-3-1 Kanda Ogawa-machi, Chiyoda-ku, Tokyo 101-0052, Japan TEL +81-3-5283-0251 FAX +81-3-5283-0258 |
| Establishment | September 28, 2010 |
| Capital | 461.9 Million Yen |
| President | CEO Hisashi Oka |
| Business Domain | Research and development, manufacture and sale of agrochemicals and fertilizers |
| Number of Employees on consolidated basis | 576(102) , as of December 31, 2022 *The numbers in parentheses are the average number of temporary employees |

Business Location

| Sapporo Sales Office | 11th Floor, FUJIFILM Sapporo Bldg., 6-1, Odori Nishi, Chuo-ku, Sapporo-shi, 060-0042, Japan TEL +81-11-200-5151 | Asi Ma |
|--|--|-------------------|
| East Japan Branch Office | 8th Floor, NBF Ogawa-machi Bldg. 1-3-1 Kanda Ogawa-machi, Chiyoda-ku, Tokyo 101-0052, Japan TEL +81-3-5283-0260 | Dri Res |
| West Japan Branch Office | 9th Floor, Honmachi Takeda Bldg. 3-1-29 Kyutaro-machi, Chuo-ku, Osaka-shi 541-0056, Japan TEL +81-6-6125-5355 | Inp |
| West Japan Branch / Shikoku Office | 12-1 Shimokubo, Himeda, Oasa-cho, Naruto-shi 779-0301, Japan TEL +81-88-684-4451 | Lak Priv OA |
| Kyushu Sales Office | 2-4-52 Shinhoka, Higashi-ku, Kumamoto-shi 862-0921, Japan TEL +81-96-360-5577 | Lim Asi |
| Naruto Factory | 615 Hanamen, Satoura, Satoura-cho, Naruto-shi 772-0021, Japan TEL +81-88-684-0210 | PT. |
| Research & Development Division | 615 Hanamen, Satoura, Satoura-cho, Naruto-shi 772-0021, Japan TEL +81-88-684-0201 | Rur Pla |
| Cultivation Research Center | 12-1 Shimokubo, Himeda, Oasa-cho, Naruto-shi 779-0301, Japan TEL +81-88-685-2890 | LID |
| | | Blu |

Board of Directors


| President, CEO | Hisashi Oka | |
|--|---------------------|---|
| Director, Board Member, Senior Executive Officer | Satoshi Kitaguchi | Production Control Division, Research & Development Division |
| Director, Board Member, Senior Executive Officer | Wataru Okumura | Overseas Business Headquarters |
| Director, Board Member, Executive Officer | Hiroki Takase | General Affairs Division, Accounting Division, Intellectual Property & Legal Section |
| Director, Board Member, Executive Officer | Izumi Suemura | Domestic Business Headquarters |
| Director, Board Member, Executive Officer | Itoko Watanabe | Personnel Division, DX |
| Director (Audit & Supervisory Committee Member) | Minoru Kimura | (Outside Director) |
| Director (Audit & Supervisory Committee Member) | Jun Ogawa | (Outside Director) |
| Director (Audit & Supervisory Committee Member) | Motonori Araki | (Outside Director) |
| Executive Officer | Shigeuchi Toshiyuki | Director Business Development Division Overseas Business Headquarters |
| Executive Officer | Yoshihiro Fujimoto | Business Development Division Overseas Business Headquarters |
| Executive Officer | Kei Hidaka | Marketing & Technical Promotion Division Domestic Business Headquarters |
| | | |

Associated Companies

| Asahi Chemical Manufacturing Co., Ltd | Establishment Address | February 9, 1952 500 Takayasu, Ikaruga-cho, Ikoma-gun, Nara TEL +81-745-74-1131 FAX +81-745-74-1961 |
|--|---|---|
| | Main Domain | Manufacturing, sales, export/import of fertilizers and other products used in horticulture and agriculture |
| Drip Fertigation Research Co., Ltd. | Establishment Address | September 1, 2004 3-4-13, Higashi Ishioka, Ishioka-shi, Ibaraki TEL +81-299-56-6752 FAX +81-299-56-6753 |
| | Main Domain | Sales of hydroponic cultivation systems and related products such as fertilizers |
| Inplanta Innovations Inc. | Establishment Address Main Domain | March, 2003 4-5-11, Namamugi, Tsurumi-ku, Yokohama-shi, Kanagawa Research and development of genetic engineering, and contracted research of plants, etc. |
| OAT&IIL India Laboratories Private Limited | Establishment Address | March, 2013 E-423, RIICO Industrial Area, Chopanki Bhiwadi -301707 Rajasthan, India |
| | Main Domain | Research and development of new crop protection products |
| OAT Pakistan Private Limited | Establishment Address | December, 2013 United Trade Centre, Office No-14, Gulshan-E-lqbal, Block-6, Main Rashid Minhas Road, Karachi, Sindh, Pakistan |
| | Main Domain | Import and sales of crop protection products |
| Asahi Chemical Europe s. r. o. | Establishment Address Main Domain | February, 2010 Lužná 716/2, 160 00 Praha 6 - Vokovice, Czech Republic Import and sales of crop protection products |
| PT. OAT MITOKU AGRIO | Establishment Address | January, 2016 JI. Taman Bendungan Asahan II No.8 Jakarta Pusat 10210, Indonesia |
| | Main Domain | Manufacturing and sales of agrochemicals and fertilizers |
| Runhe (Zhoushan) Plant Science Co., Ltd. | Establishment Address | May, 2016 Ruotiao Village, Xiushan Island, Daishan County, Zhoushan City, Zhejiang Province, P.R. of China. |
| | Main Domain | Manufacturing and sales of drip fertigation systems and fertilizers |
| LIDA Plant Research, S.L. | Establishment Address | 1987 Parque Industrial Juan Carlos I - C/Granja,12-46440 ALMUSSAFES (Valencia)SPAIN |
| | Main Domain | Development, manufacturing, and sales of nutritional products and biostimulants and distribution of plant protection products |
| Blue Wave Holding B.V. | Establishment Address Main Domain | 2014 (establishment of holding company) Gooimeer 7, 1411 DD Naarden P.O. Box.5300,1410 AH Naarden, The Netherlands Development, manufacturing and sale of post-harvest flower and plant care solutions |

History

- **1950** Otsuka Pharmaceutical Factory divested the organic chemicals business to Otsuka Chemicals and Pharmaceuticals Co., Ltd.
- 1952 Started manufacturing and sales of agrochemicals
- **1953** Started selling a tobacco sucker inhibitor (OMH+30)
- 1963 Started selling gravel culture fertilizer
- 1964 Started selling the foliar fertilizer Samppi
- 1976 Started selling the herbicide Parazet
- 1979 Started selling the agricultural material disinfectant Ichiban, the insecticide Rubitocs and the molluscicide Namekit
- 1980 Started selling the fungicide Unitekt
- **1984** Changed the company name to Otsuka Chemical Co., Ltd.
- **1986** Started selling the herbicide Myzet and the insecticide
- **1992** Started selling the insecticide Oleate and the calcium supplement Calplus
- 1993 Started selling the insecticide Orion
- 1995 Started selling the insecticide Sted Granules
- 1996 Started selling the insecticide Ondaia
- **1997** Started selling the turf coloring agent Greenway
- **1998** Started selling Misaki for extending the life of cut flowers Started nationwide sales of the Drip Fertigation System
- **1999** Started selling Otsuka Judge Box Granules, an insecticide and fungicide specifically for rice seedling boxes
- 2000 Started selling the insecticides Grand Oncol, Oncol Micro Capsules, Ondaia Ace and Deraus Oncol Started selling the fungicide Alshine
- 2002 Otsuka Chemical Co., Ltd. was newly established to receive the chemical products and agrochemicals and fertilizer business Started selling the insecticide Hachi-Hachi EC
- 2007 Otsuka Chemical started selling the acaricide Danisaraba
- 2010 Established Otsuka AgriTechno Co., Ltd. and became independent from Otsuka Chemical Co., Ltd. by way of MBO
- 2011 Started the manufacturing and sales of the rice paddy herticides Benfuresate and Benzofenap which were acquired from the German company Bayer Crop Science
- 2012 Acquired Asahi Chemical Manufacturing Co., Ltd. as a 100% subsidiary
- 2013 Established OAT&IIL India Laboratories Private Limited based on an agreement with Insecticides (India) Limited Launched the fungicide Gatten in Japan
- 2014 Changed the company name to OAT Agrio Co., Ltd. Listed on the Second Section of Tokyo Stock Exchange
- 2015 Listed on The First Section of Tokyo Stock Exchange
- 2016 Established PT. OAT MITOKU AGRIO Established Runhe (Zhoushan) Plant Science Co., Ltd. Established OAT Agri Frontier Co., Ltd.
- 2017 Participate in establishment of Japan Generic Agrochemicals Association Started selling a new drip fertigation system "TT series" Acquired ISO 9001:2015 certification
- 2018 Established Japan Biostimulant Association as a founder Established H-New Corporation Acquired LIDA Plant Research, S.L. and CAPA Ecosystems, S.L. Acquired Inplanta Innovations Inc. as a 100% subsidiary Acquired Blue Wave Holding B.V including Chrysal and their associated companies
- 2019 Obtained EU pesticide registration approval for Flutianil Obtained GLOBAL GAP certificate
- 2020 Obtained California pesticide registration approval in USA
- 2022 Due to the revision of the market classification of the Tokyo Stock Exchange, Shifted from the First Section to Prime Market.




Financial Highlights (Consolidated)


ΑΟΑΤ9

(Unit: ¥ million)


| | 2018/12 | 2019/12 | 2020/12 | 2021/12 | 2022/12 | |
|-------------|---------|---------|---------|---------|---------|--|
| | 15,278 | 21,909 | 20,288 | 22,678 | 26,960 | |
| | 6,968 | 9,389 | 9,464 | 10,707 | 12,660 | |
| | 1,743 | 1,077 | 1,512 | 2,001 | 3,346 | |
| o owners of | 1,261 | 4 | 837 | 1,456 | 2,261 | |
| | 30,684 | 29,724 | 28,848 | 28,346 | 31,009 | |
| | 7,532 | 6,807 | 7,632 | 9,096 | 11,949 | |









Total assets
















Management Indicators (Consolidated)






Note: The amount of total assets, inventory and fixed assets are calculated using the average of the figures at the beginning and end of the period.






Note: Net sales per employee, operating income per employee and net income per employee are calculated using the average number of employees during the period.



| | 2018/12 | 2019/12 | 2020/12 | 2021/12 | 2022/12 |
|-------------------------------|---------|---------|---------|---------|---------|
| Free cash flow | △10,420 | 1,928 | 1,679 | 3,824 | 847 |
| Capital expenditure | 272 | 375 | 184 | 288 | 381 |
| Depreciation and amortization | 411 | 1,484 | 1,412 | 1,416 | 1,484 |
| | | | | | |

Note: Free cash flow= cash flows from operating activities + cash flows from investing activities

Other Investment Indicators/Indicators per share



| | 2010/12 | 2019/12 | 4 |
|----------------------------|---------|---------|---|
| Return on equity (ROE) (%) | 19.91 | 0.06 | |
| Return on assets (ROA) (%) | 8.13 | 2.77 | |
| Net income per share (yen) | 116.56 | 0.43 | |
| Net assets per share (yen) | 623.63 | 562.06 | |


Notes1: Shareholder's equity and total assets are calculated using the average of the figures at the beginning and end of the period. Notes2: Net income per share and net assets per share are retrospectively adjusted according to two for one stock split for shares of common stock on March 1, 2022.



Financial Statements (Consolidated)

| 2020/12 | 2021/12 | 2022/12 |
|---------|---------|---------|
| 37.1 | 41.5 | 47.6 |
| 2.8 | 3.7 | 5.9 |
| 1.5 | 2.7 | 4.0 |
| 537 | 556 | 576 |
| 92 | 92 | 102 |

(Unit: %/yen)



| | 2021/12 | 2022/12 |
|---|---------|---------|
| Assets | | |
| Current assets | | |
| Cash and deposits | 3,651 | 3,614 |
| Notes and accounts receivable- trade | 5,275 | _ |
| Notes receivable - trade | _ | 452 |
| Electronically recorded monetary claims - operating | - | 62 |
| Accounts receivable - trade | _ | 5,239 |
| Merchandise and finished goods | 2,682 | 3,443 |
| Work in process | 605 | 1,071 |
| Raw materials and supplies | 1,687 | 2,345 |
| Other | 664 | 750 |
| Allowance for doubtful accounts | △54 | △60 |
| Total current assets | 14,513 | 16,920 |
| Non-current assets | | |
| Property, plant and equipment | | |
| Buildings and structures, net | 1,222 | 1,176 |
| Machinery, equipment and vehicles, net | 698 | 745 |
| Land | 1,037 | 1,090 |
| Leased assets, net | 507 | 462 |
| Other, net | 242 | 303 |
| Total property, plant and equipment | 3,708 | 3,779 |
| Intangible assets | | |
| Goodwill | 6,085 | 5,960 |
| Software | 98 | 184 |
| Customer relation assets | 2,651 | 2,650 |
| Other | 357 | 382 |
| Total intangible assets | 9,193 | 9,177 |
| Investments and other assets | | |
| Investment securities | 370 | 428 |
| Shares of subsidiaries and associates | 74 | 82 |
| Deferred tax assets | 184 | 313 |
| Other | 301 | 307 |
| Total investments and other assets | 930 | 1,132 |
| Total non-current assets | 13,833 | 14,089 |
| Fotal assets | 28,346 | 31,009 |
| | | |

| · · · · · · · · · · · · · · · · · · · | 2021/12 | 2022/12 |
|---|---------|---------|
| Liabilities | | |
| Current liabilities | | |
| Notes and accounts payable – trade | 3,076 | 2,954 |
| Short-term loans payable | 4,728 | 5,865 |
| Accounts payable - other | 617 | 686 |
| Income taxes payable | 465 | 646 |
| Provision for bonuses | 33 | 37 |
| Provision for loss on compensation for damage | 21 | 23 |
| Refund liabilities | 105 | 128 |
| Other | 1,342 | 1,275 |
| Total current liabilities | 10,392 | 11,617 |
| Non-current liabilities | | |
| Long-term loans payable | 7,401 | 5,951 |
| Retirement benefit liability | 161 | 282 |
| Deferred tax liabilities | 915 | 883 |
| Other | 379 | 324 |
| Total non-current liabilities | 8,858 | 7,442 |
| Total liabilities | 19,250 | 19,060 |
| Net assets | | |
| Shareholders' equity | | |
| Capital stock | 461 | 461 |
| Capital surplus | 2,404 | 2,410 |
| Retained earnings | 5,882 | 7,906 |
| Treasury shares | △433 | △408 |
| Total shareholders' equity | 8,314 | 10,371 |
| Accumulated other comprehensive income | | |
| Valuation difference on available- for-sale securities | 83 | 72 |
| Foreign currency translation adjustment | △172 | 632 |
| Remeasurements of defined benefit plans | 45 | △44 |
| Total accumulated other comprehensive income | △43 | 660 |
| Non-controlling interests | 825 | 917 |
| Total net assets | 9,096 | 11,949 |
| Total liabilities and net assets | 28,346 | 31,009 |

| | 2021/12 | 2022/1 |
|---|---------|--------|
| Net sales | 22,678 | 26,96 |
| Cost of sales | 11,971 | 14,29 |
| Gross profit | 10,707 | 12,66 |
| Selling, general and administrative expenses | 8,705 | 9,31 |
| Operating income | 2,001 | 3,34 |
| Non-operating income | | |
| Interest income | 11 | 1 |
| Dividend income | 7 | |
| Insurance fee income | 29 | 3 |
| Foreign exchange gains | 82 | 15 |
| Share of profit of entities accounted for using equity method | 7 | |
| Other | 35 | 2 |
| Total non-operating income | 174 | 23 |
| Non-operating expenses | | |
| Interest expenses | 171 | 18 |
| Commission for purchase of treasury shares | 2 | |
| Other | 13 | 1 |
| Total non-operating expenses | 186 | 19 |
| Ordinary income | 1,989 | 3,38 |
| Extraordinary income | | |
| Gain on sales of investment securities | 78 | - |
| Gain on sales of non-current assets | 3 | 1 |
| Gain on sale of businesses | 234 | - |
| Total extraordinary income | 316 | 1 |
| Extraordinary losses | | |
| Loss on retirement of non-current assets | 1 | |
| Impairment loss | 8 | 1 |
| Loss on valuation of investment securities | 18 | - |
| Loss on valuation of shares of subsidiaries and associates | 7 | - |
| Total extraordinary losses | 36 | 2 |
| Profit before income taxes | 2,269 | 3,37 |
| Income taxes-current | 838 | 1,19 |
| Income taxes-deferred | △115 | △18 |
| Total income taxes | 722 | 1,00 |
| Profit | 1,546 | 2,36 |
| Profit attributable to non-controlling interests | 89 | 10 |
| Profit attributable to owners of parent | 1,456 | 2,26 |

| Pi | rofit |
|----|--|
| С | ther comprehensive i |
| | Valuation difference for-sale securities |
| | Foreign currency tran adjustment |
| | Remeasurements of plans, net of tax |
| С | omprehensive income |
| | Comprehensive inco attributable to |
| | Comprehensive inco to owners of parent |
| | Comprehensive incom non-controlling interes |

Consolidated Balance Sheets

(Unit: ¥ million)

Consolidated Statements of Cash Flows (Unit: ¥ million)

| | 2021/12 | 2022/12 |
|--|---------------|-----------------|
| Cash flows from operating activities | | |
| Profit before income taxes | 2,269 | 3,378 |
| Depreciation | 825 | 864 |
| Amortization of goodwill | 591 | 620 |
| Loss (gain) on sale of businesses | △234 | - |
| Loss (gain) on valuation of investment securities | △78 | - |
| Loss on sales of non-current assets | 1 | 4 |
| Loss (gain) on sales of non-current assets | ∆3 | △17 |
| Impairment loss | 8 | 19 |
| Loss (gain) on valuation of investment securities | 18 | - |
| Share of loss (profit) of entities accounted for using equity method | △7 | ∆3 |
| Insurance claim income | △29 | △39 |
| Interest and dividend income | △19 | △19 |
| Share-based remuneration expenses | 22 | 32 |
| Foreign exchange losses (gains) | 10 | △0 |
| Interest expenses | 171 | 182 |
| Increase (decrease) in net defined benefit liability | △121 | 120 |
| Increase (decrease) in allowance for doubtful accounts | △2 | 1 |
| Increase (decrease) in refund liability | △22 | 22 |
| Increase (decrease) in provision for bonuses | 2 | 3 |
| Decrease (increase) in trade receivables | 204 | △306 |
| Decrease (increase) in inventories | △429 | △1,698 |
| Increase (decrease) in trade payables | 996 | △216 |
| Increase (decrease) in accounts payable-other | 13 | △43 |
| Other, net | 131 | △330 |
| Subtotal | 4,320 | 2,575 |
| Interest and dividends received | 24 | 3 |
| Interest paid | △173 | △153 |
| Compensation for damage paid | △25 | |
| Income taxes paid | △570 | △1,048 |
| Proceeds from insurance income | 29 | 39 |
| Net cash provided by (used in) operating activities | 3,603 | 1,416 |
| Cash flows from investing activities | -, | ., |
| Payments into time deposits | △390 | △106 |
| Proceeds from withdrawal of time deposits | 476 | - |
| Purchase of property, plant and equipment | △259 | △288 |
| Proceeds from sales of property, plant and equipment | 6 | 19 |
| Purchase of intangible assets | △146 | △120 |
| Proceeds from sales of investment securities | 288 | _ |
| Purchase of sales of investment securities | | △73 |
| Proceeds from sales of shares of subsidiaries and associates | 12 | |
| Proceeds from sale of businesses | 234 | _ |
| Other. net | 0 | |
| Net cash provided by (used in) investing activities | 221 | |
| Cash flows from financing activities | 221 | |
| Net increase (decrease) in short-term loans payable | △1,801 | 811 |
| Proceeds from long-term borrowings | | 1,678 |
| Repayments of long-term borrowings | △1,416 | △3,045 |
| Repayments of lease obligations | △1,410 | △171 |
| Purchase of treasury shares | △140 | |
| Dividends paid | △299 | △237 |
| | △215 | △237 |
| Dividends paid to non-controlling interests Other, net | | |
| Net cash provided by (used in) financing activities | △3,936 | <u>∧1020</u> |
| | | △1,029 38 |
| Effect of exchange rate change on cash and cash equivalents | 97 ^ 12 | 38 |
| Net increase (decrease) in cash and cash equivalents | △12 2.5.27 | △143 2 5 1 4 |
| Cash and cash equivalents at beginning of period | 3,527 | 3,514 |
| Cash and cash equivalents at end of period | 3,514 | 3,371 |

Consolidated Statements of Income (Unit: ¥ million)

Consolidated Statements of Comprehensive Income (Unit: ¥ million)

| | 2021/12 | 2022/12 |
|-------------------------|---------|---------|
| | 1,546 | 2,369 |
| ncome | 511 | 756 |
| on available- | △6 | △11 |
| slation | 430 | 858 |
| defined benefit | 87 | △89 |
| | 2,057 | 3,126 |
| ne | | |
| ne attributable | 1,922 | 2,966 |
| e attributable to ts | 135 | 160 |
| | | |